The U.S. Food and Drug Administration approved a blood test to detect signs of Alzheimer’s disease on Aug. 24, 2026 [1].
This approval marks a shift toward less invasive diagnostics for a condition that typically requires expensive imaging or painful spinal taps. By providing a faster way to identify biomarkers, the test allows for earlier intervention and more accurate patient management.
Multiple companies have seen their diagnostic tools cleared by the agency. C2N Diagnostics received clearance for its PrecivityAD2 test [3], while Roche and Eli Lilly also had blood tests cleared [4]. For the Roche test, the FDA noted compatibility with cobas e 402 and cobas e 801 laboratory instruments [5].
The diagnostic tool is intended for patients as young as 40 who exhibit potential cognitive symptoms of the condition [3]. Because it is minimally invasive, the test can help doctors identify symptoms of Alzheimer’s disease earlier than previous methods allowed, Zachary Folk of Forbes said [4].
However, the FDA has not approved the test for general population use. The test is not meant for routine screening but can be pivotal for a diagnosis when cognitive problems are causing doctors to suspect the disease, Washington Post staff said [1].
Medical professionals can use the test for rule-in and rule-out assessments to determine if a patient's cognitive decline is linked to Alzheimer's [5]. This process helps narrow down the cause of dementia in patients already showing symptoms, reducing the need for more invasive procedures.
“The new test promises to be “minimally invasive” and can help doctors identify symptoms of Alzheimer’s disease earlier.”
The transition to blood-based biomarkers for Alzheimer's represents a significant leap in accessibility for neurological diagnostics. While not a screening tool for healthy adults, this approval streamlines the clinical pathway for patients with cognitive impairment, potentially increasing the number of people who receive a formal diagnosis early enough to access emerging disease-modifying therapies.
